Supplemental material
Current Medical Research and Opinion
Volume 36, 2020 - Issue 5
Related Research Data
Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.
Source:
Informa UK Limited
The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.
Source:
Mary Ann Liebert Inc
Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Source:
Informa UK Limited
A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence
Source:
Wiley
A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Source:
SAGE Publications
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Source:
Elsevier BV
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
Source:
Informa UK Limited
Norfolk QOL-DN
Source:
Wiley
Online registry for mutations in hereditary amyloidosis including nomenclature recommendations.
Source:
Wiley
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
Source:
BioMed Central
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Source:
Massachusetts Medical Society
Linking provided by
